title: Problems in the management of chronic hepatitis B with interferon: experience in a randomized, multicentre study.
abstract: In a multicentre trial, 82 patients known to be hepatitis B e antigen and hepatitis B virus DNA positive for at least 1 year, with elevated serum alanine aminotransferase levels and chronic liver lesions on biopsy, were randomized to receive either recombinant interferon alfa-2a at a dose of 4.5 million units thrice weekly for 4 months or no treatment. At the end of therapy, viral DNA clearance and aminotransferase normalization were significantly (p less than 0.05) more frequent in treated patients than in controls. After 16 months' follow up, the difference was still significant for hepatitis B e antigen clearance and transaminase normalization. Hepatitis B virus DNA reactivation was observed during follow up in 43% of treated patients and 50% of controls. Improvements in liver inflammation were observed in patients on interferon. High pre-treatment serum aminotransferase levels, female sex and a low score for fibrosis in the initial biopsy were predictive factors significantly (p less than 0.05) associated with termination of hepatitis B virus replication in treated cases. These results indicate that interferon is effective in inducing clearance of HBV from serum and improvement of biochemical and histological parameters of liver disease. However, a more prolonged regimen of therapy may be required to obtain stable suppression of hepatitis B virus replication.
authors.affiliation: Istituto di Clinica Medica, University of Sassari, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Realdi
authors.forename: G
authors.initials: G
authors.lastname: Fattovich
authors.forename: G
authors.initials: G
authors.lastname: Pastore
authors.forename: F
authors.initials: F
authors.lastname: Caredda
authors.forename: F
authors.initials: F
authors.lastname: Noventa
authors.forename: T
authors.initials: T
authors.lastname: Santantonio
authors.forename: M
authors.initials: M
authors.lastname: Moroni
authors.forename: D
authors.initials: D
authors.lastname: Criscuolo
authors.forename: D
authors.initials: D
authors.lastname: Maladorno
authors.forename: M
authors.initials: M
authors.lastname: Rugge
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D015415:Biomarkers / Q000097:blood; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000097:blood / Q000473:pathology / Q000628:therapy*; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006513:Hepatitis B e Antigens / Q000032:analysis; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008099:Liver / Q000473:pathology; D008297:Male; D011994:Recombinant Proteins
chemical_list: D015415:Biomarkers; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D000410:Alanine Transaminase